Analysis of ANC Levels after Filgrastim Therapy in Acute Leukemia Children with Neutropenia

Cytotoxic chemotherapy suppresses the hematopoietic system, and the most serious hematologic toxicity is neutropenia. This can decrease a risk of infection that causes delays in treatment and reduction of dose intensity, which reduces therapeutic outcome. Filgrastim is used to increase neutrophils l...

Full description

Bibliographic Details
Main Authors: Reta Anggraeni Widya, Susanto Nugroho, Sri Winarsih, Yulistiani Yulistiani
Format: Article
Language:English
Published: Universitas Airlangga 2021-01-01
Series:Folia Medica Indonesiana
Subjects:
Online Access:https://e-journal.unair.ac.id/FMI/article/view/24287
id doaj-69ea4d4638334e558bac17f51ca8c583
record_format Article
spelling doaj-69ea4d4638334e558bac17f51ca8c5832021-08-03T04:14:26ZengUniversitas AirlanggaFolia Medica Indonesiana2355-83932599-056X2021-01-01551101610.20473/fmi.v55i1.2428711648Analysis of ANC Levels after Filgrastim Therapy in Acute Leukemia Children with NeutropeniaReta Anggraeni Widya0Susanto Nugroho1Sri Winarsih2Yulistiani Yulistiani3Master Program of Clinical Pharmacy, Universitas Airlangga, SurabayaDepartment of Pediatrics, Nephrology Division, Dr. Saiful Anwar Teaching Hospital, MalangPharmacy Installation of Dr. Saiful Anwar Teaching Hospital, MalangMaster Program of Clinical Pharmacy, Universitas Airlangga, SurabayaCytotoxic chemotherapy suppresses the hematopoietic system, and the most serious hematologic toxicity is neutropenia. This can decrease a risk of infection that causes delays in treatment and reduction of dose intensity, which reduces therapeutic outcome. Filgrastim is used to increase neutrophils level whose therapeutic effect is unknown. The effectiveness of filgrastim is based on the ANC level pre- and post-therapy. This study aimed to analyze the use of filgrastim on ANC level changes in acute leukemia children with neutropenia, and to analyze the patient that achieve ANC level’s targeted therapy = 1000 cell/mm3. A prospective observational study with a longitudinal design was conducted from June to October 2016. The inclusion criteria of the study were patients who diagnosed acute leukemia with neutropenia and received filgrastim 10 µg/kgBW for 3, 4, 5 days. Patients’ ANC levels were measured before and after filgrastim therapy. This study has been approved its ethical clearance by Dr. Saiful Anwar Hospital, Malang. Data were obtained on the basis of neutropenic episodes, followed by 7 episodes of obtaining filgrastim for 3 days, 1 episode of obtaining filgrastim for 4 days, and 7 episodes of obtaining filgrastim for 5 days. Thus, it consists of 15 episodes. In 3 days, ANC levels increased by 9.5 fold from 381.3 ± 91.8 cell/mm3 to 3984.9 ± 426.8 cell/mm3, but in 5 days, ANC levels decreased by 0.9 fold from 200.9 cell/mm3 ± 98.2 to 189.7 ± 14.2 cell/mm3. Filgrastim was able to increased the ANC levels around nine fold for 3 days of theraphy. There were 53% neutropenia patients who achieved the goal of therapy. Filgrastim therapy with dose 10 µg/kgBW for 3 to 5 days has been able to reach the therapeutic target of 53% in acute leukemia children with neutropenia. The increased levels of ANC maximum was reached on the third day with increased levels of 9.5 fold.https://e-journal.unair.ac.id/FMI/article/view/24287filgrastimabsolute neutrophyl count (anc)acute leukemiachemotherapy induce neutropenia (cin)
collection DOAJ
language English
format Article
sources DOAJ
author Reta Anggraeni Widya
Susanto Nugroho
Sri Winarsih
Yulistiani Yulistiani
spellingShingle Reta Anggraeni Widya
Susanto Nugroho
Sri Winarsih
Yulistiani Yulistiani
Analysis of ANC Levels after Filgrastim Therapy in Acute Leukemia Children with Neutropenia
Folia Medica Indonesiana
filgrastim
absolute neutrophyl count (anc)
acute leukemia
chemotherapy induce neutropenia (cin)
author_facet Reta Anggraeni Widya
Susanto Nugroho
Sri Winarsih
Yulistiani Yulistiani
author_sort Reta Anggraeni Widya
title Analysis of ANC Levels after Filgrastim Therapy in Acute Leukemia Children with Neutropenia
title_short Analysis of ANC Levels after Filgrastim Therapy in Acute Leukemia Children with Neutropenia
title_full Analysis of ANC Levels after Filgrastim Therapy in Acute Leukemia Children with Neutropenia
title_fullStr Analysis of ANC Levels after Filgrastim Therapy in Acute Leukemia Children with Neutropenia
title_full_unstemmed Analysis of ANC Levels after Filgrastim Therapy in Acute Leukemia Children with Neutropenia
title_sort analysis of anc levels after filgrastim therapy in acute leukemia children with neutropenia
publisher Universitas Airlangga
series Folia Medica Indonesiana
issn 2355-8393
2599-056X
publishDate 2021-01-01
description Cytotoxic chemotherapy suppresses the hematopoietic system, and the most serious hematologic toxicity is neutropenia. This can decrease a risk of infection that causes delays in treatment and reduction of dose intensity, which reduces therapeutic outcome. Filgrastim is used to increase neutrophils level whose therapeutic effect is unknown. The effectiveness of filgrastim is based on the ANC level pre- and post-therapy. This study aimed to analyze the use of filgrastim on ANC level changes in acute leukemia children with neutropenia, and to analyze the patient that achieve ANC level’s targeted therapy = 1000 cell/mm3. A prospective observational study with a longitudinal design was conducted from June to October 2016. The inclusion criteria of the study were patients who diagnosed acute leukemia with neutropenia and received filgrastim 10 µg/kgBW for 3, 4, 5 days. Patients’ ANC levels were measured before and after filgrastim therapy. This study has been approved its ethical clearance by Dr. Saiful Anwar Hospital, Malang. Data were obtained on the basis of neutropenic episodes, followed by 7 episodes of obtaining filgrastim for 3 days, 1 episode of obtaining filgrastim for 4 days, and 7 episodes of obtaining filgrastim for 5 days. Thus, it consists of 15 episodes. In 3 days, ANC levels increased by 9.5 fold from 381.3 ± 91.8 cell/mm3 to 3984.9 ± 426.8 cell/mm3, but in 5 days, ANC levels decreased by 0.9 fold from 200.9 cell/mm3 ± 98.2 to 189.7 ± 14.2 cell/mm3. Filgrastim was able to increased the ANC levels around nine fold for 3 days of theraphy. There were 53% neutropenia patients who achieved the goal of therapy. Filgrastim therapy with dose 10 µg/kgBW for 3 to 5 days has been able to reach the therapeutic target of 53% in acute leukemia children with neutropenia. The increased levels of ANC maximum was reached on the third day with increased levels of 9.5 fold.
topic filgrastim
absolute neutrophyl count (anc)
acute leukemia
chemotherapy induce neutropenia (cin)
url https://e-journal.unair.ac.id/FMI/article/view/24287
work_keys_str_mv AT retaanggraeniwidya analysisofanclevelsafterfilgrastimtherapyinacuteleukemiachildrenwithneutropenia
AT susantonugroho analysisofanclevelsafterfilgrastimtherapyinacuteleukemiachildrenwithneutropenia
AT sriwinarsih analysisofanclevelsafterfilgrastimtherapyinacuteleukemiachildrenwithneutropenia
AT yulistianiyulistiani analysisofanclevelsafterfilgrastimtherapyinacuteleukemiachildrenwithneutropenia
_version_ 1721224192224919552